Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
Nov 06, 2008 04:02 PM
- Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
Oct 29, 2008 07:30 PM
- Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
Oct 21, 2008 08:13 PM
- Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
Sep 29, 2008 06:15 PM
- Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
Sep 15, 2008 07:00 PM
- Cadence Pharmaceuticals Appoints Todd Rich, M.D. to its Board of Directors and Names Malcolm Lloyd-Smith as Senior Vice President, Regulatory Affairs and Quality Assurance
Aug 28, 2008 05:16 PM
- Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
Aug 27, 2008 08:00 PM
- Cadence Pharmaceuticals Reports Second Quarter 2008 Financial Results and Provides Overview of Clinical Programs
Aug 07, 2008 07:31 AM
- Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
Aug 04, 2008 05:15 PM
- Cadence Pharmaceuticals Announces FDA Concurrence With Clinical Development Plan for Acetavance(TM)
Jul 30, 2008 04:02 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
CADX
|
Compare to S&P
|
| YTD |
-55.18 %
|
-26.57 %
|
| 4 Weeks |
1.99 %
|
10.24 %
|
| 12 Weeks |
-33.40 %
|
-7.68 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 12.20 %
|
|
EPS Growth in Last Year: 20.00 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
|
